Risk factors
aTYR PHARMA (ATYR) risk factors
Item 1A of every aTYR PHARMA Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors81 risks5 new6 dropped13 reworded
aTyr Pharma faces new securities class action litigation and Nasdaq delisting risk as its stock traded below $1.00.
Filed Mar 05, 2026 - FY2024 10-K risk factors82 risks
The company faces extensive clinical trial, regulatory, and manufacturing risks as a pre-commercial biotherapeutics firm dependent on efzofitimod. There is no established FDA regulatory pathway for pulmonary sarcoidosis, threatening approval even if trials succeed. The firm relies entirely on third-party contract manufacturers and clinical research organizations.
Filed Mar 13, 2025